Carbachol/brimonidine
combination eye drop
Carbachol/brimonidine, sold under the brand name Yuvezzi, is a fixed-dose combination medication used for the treatment of presbyopia. It contains carbachol, a cholinergic agonist; and brimonidine, as the salt brimonidine tartrate, an alpha-adrenergic receptor agonist. It is given via an eye drop.
Carbachol/brimonidine was approved for medical use in the United States in January 2026.
Medical uses
The combination is indicated for the treatment of presbyopia in adults.
Mechanism of action
The combination works by combining carbachol and brimonidine tartrate, the tartrate salt form of brimonidine to work together to constrict the pupil, called miosis.
Carbachol
Carbachol constricts the pupil, creating a pinhole effect which lets only the most direct and focused light into the eye. This results in closer objects appearing clearer.
Brimonidine
Brimonidine keeps the pupil from widening again by relaxing opposing muscles in the iris and reducing unnecessary muscle activity. This results in the pupil-constricting effect carbachol does to last longer and remain more controlled.
Begin with the source’s own compact description: “Carbachol/brimonidine” is combination eye drop. The dossier treats that line as a proposition to test through Carbachol, brimonidine and combination, not as a finished interpretation.
Why this record matters
The phrase “combination eye drop” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Sep 20, 2026. The linked authority identifier is Q140681008. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2026.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Carbachol/brimonidine”, its source revision and the description used here.
- Expand the search: follow Carbachol/brimonidine primary sources, Carbachol/brimonidine archive and Carbachol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Carbachol/brimonidine”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Carbachol/brimonidine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.